UNSPSC 51422339: Dexamethasone palmitate

This classification denotes a therapeutic glucocorticoid and antiemetic agent C38H59FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 601XWN7060, chemically known as 9-fluoro-11,17-dihydroxy-16-methyl-21-((1- oxohexadecyl)oxy)pregna-1,4-diene-3,20-dione (11.beta.,16.alpha.)-, but more generally known as dexamethasone palmitate, which bears US NIH Compound Identifier 63044. European Medicines Agency schedules Dexamethasone palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01611MIG.

UNSPSC 51422339 Dexamethasone palmitate is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity under this code shows a mismatch with its abstract scope. The single recent opportunity tagged to this code — Seminole County, Florida's IFB for Naloxone and Drug Deactivation Systems — involves emergency medical supplies and harm-reduction products rather than dexamethasone palmitate itself. State and local governments appear to use this code inconsistently or the tagging reflects a broader pharmaceutical procurement category in practice rather than the specific active pharmaceutical ingredient the code name suggests.

Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. The procurement required electronic bid submission through the county's e-Procurement Portal, with vendors responsible for all shipping and delivery costs, E-Verify compliance, drug-free workplace certification, workers' compensation and commercial general liability insurance, and a three-month probationary termination clause. The contract structure included a two-year initial term with a one-year renewal option and potential FEMA funding, which introduced additional federal compliance requirements under the Clean Air Act and Federal Water Pollution Control Act. No explicit set-aside designations or restrictions for disadvantaged enterprises were specified. The mismatch between the code's nominal pharmaceutical scope and the actual goods being procured — emergency response supplies — suggests this code may see limited relevant activity for vendors focused on pharmaceutical manufacturing or distribution.